The question seems to be based on a misunderstanding, as Tigecycline is indeed already off-patent.

Tigecycline is an antibiotic that was initially approved by the FDA in 2005 for the treatment of various bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. It is a tetracycline derivative and functions by inhibiting protein synthesis in bacteria [2].

According to DrugPatentWatch, Tigecycline's patent expired in 2017 [1]. This means that other pharmaceutical companies can now produce and sell generic versions of Tigecycline, leading to increased competition and potentially lower prices for the medication.

It is important to note that the off-patent status of Tigecycline does not affect its safety or efficacy. The drug's mechanism of action and therapeutic uses remain the same, regardless of who manufactures it [3].

In summary, Tigecycline is a widely used antibiotic that has been off-patent since 2017. Its therapeutic uses and mechanism of action remain unchanged, and its off-patent status may lead to increased competition and lower prices for the medication.

Sources:

[1] <https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE>
[2] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/>
[3] <https://www.cff.org/managing-cf/antibiotics>